metsera glp 1 Is This the First Real Threat to Lilly and Novo? Metsera's Stunning New Data for Once Monthly Amylin Agonist Metsera's GLP-1 Receptor Agonist MET-097i
Description
Oral NSAIDs should be used cautiously, at the lowest effective dose for the shortest duration, and avoided if you are dehydrated or experiencing persistent vomiting or diarrhoea due to increased risks of kidney problems and gastrointestinal effects
A 2025 letter in Diabetes Care argues that microdosing via multidose pens can help patients who struggle with gastrointestinal side effects by allowing smaller, incremental dose adjustments, though the authors emphasize this is a pragmatic, clinician-directed strategy
The program focuses on calories and nutrient density, while also teaching about portion size
[DOI] [PubMed] [Google Scholar] 56.Jafar A.B., Jacob J., Kao W.K., Ho T
